Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.60 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.60 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.60 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.59 |
| ▸ | AGXT | P21549 | 1/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.45 |
| ▸ | IDH1 | O75874 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7340276 | 1.00 | CYP2A6 (0.60) | CYP2A6ASIC3LOXL2ADRB2AGXT | |
| SCHEMBL7345698 | 0.89 | CYP2A6 (0.56) | CYP2A6ASIC3LOXL2ADRB2AGXT | |
| SCHEMBL346786 | 0.89 | CYP2A6 (0.56) | CYP2A6ASIC3LOXL2ADRB2AGXT | |
| SCHEMBL368353 | 0.87 | CYP2A6 (0.55) | CYP2A6ASIC3LOXL2ADRB2AGXT | |
| SCHEMBL24614167 | 0.85 | CYP2A6 (0.53) | CYP2A6ASIC3LOXL2ADRB2AGXT | |
| SCHEMBL9347774 | 0.85 | CYP2A6 (0.53) | CYP2A6ASIC3LOXL2ADRB2AGXT | |
| SCHEMBL1687607 | 0.85 | CYP2A6 (0.53) | CYP2A6ASIC3LOXL2ADRB2AGXT | |
| SCHEMBL9347724 | 0.85 | CYP2A6 (0.53) | CYP2A6ASIC3LOXL2ADRB2AGXT | |
| SCHEMBL31362124 | 0.84 | CYP2A6 (0.56) | CYP2A6ASIC3LOXL2ADRB2AGXT | |
| SCHEMBL3413507 | 0.83 | CYP2A6 (0.64) | CYP2A6ASIC3LOXL2ADRB2AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127266-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-04-28 | — | — | US | disclosed |
| US-11225480-B2 | Malic enzyme inhibitors | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-01-18 | — | — | US | disclosed |
| WO-2021123237-A1 | 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE | Oxford Drug Design Limited (GB) | 2021-06-24 | — | — | WO | disclosed |
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2021-04-22 | — | — | US | disclosed |
| WO-2021074898-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2021-04-22 | — | — | WO | disclosed |
| EP-2934563-B1 | ANTIMICROBIAL COMPOUNDS, THEIR SYNTHESIS AND APPLICATIONS THEREOF | JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENT RESEARCH (IN) | 2020-07-08 | — | — | EP | disclosed |
| US-20120196845-A1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-08-02 | — | — | US | disclosed |
| US-20120190868-A1 | SUBSTITUTED BENZOCHALCOGENOACENE COMPOUND, THIN FILM COMPRISING THE COMPOUND, AND ORGANIC SEMICONDUCTOR DEVICE INCLUDING THE THIN FILM | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2012-07-26 | — | — | US | disclosed |
| US-20110144090-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION | 2011-06-16 | — | — | US | disclosed |
| US-7390804-B2 | N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-24 | — | — | US | disclosed |
| US-6342610-B2 | COMPOUNDS SUCH AS N-(4-BROMO-3-METHYL-5-ISOXAZOLYL)-2-N-BENZYLBENZO(B)THIOPHENE-3-SUFONAMIDE ADMINISTERED AS ENDOTHELIN PEPTIDE RECEPTOR ANTAGONISTS | TEXAS BIOTECHNOLOGY CORP. | 2002-01-29 | — | — | US | disclosed |
| US-6331637-B1 | N-Alkyl, N-Alkenyl, N-Alkynyl, N-Aryl and N-fused bicyclo or tricyclo thienyl-, furyl-,and Pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION | 2001-12-18 | — | — | US | disclosed |
| US-20010021714-A1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | ENCYSIVE PHARMACEUTICALS INC. | 2001-09-13 | — | — | US | disclosed |
| EP-1048657-A1 | Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2000-11-02 | — | — | EP | disclosed |
| US-5962490-A | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1999-10-05 | — | — | US | disclosed |
| US-5874295-A | Arthrobacter sp. and its use for the desulfuration of fossil fuels | ENIRICERCHE S.P.A. (IT) | 1999-02-23 | — | — | US | disclosed |
| EP-0819125-A1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-01-21 | — | — | EP | disclosed |
| EP-0795603-A2 | Arthrobacter sp. and its use for the desulfuration of fossil fuels | ENIRICERCHE S.p.A. (IT) | 1997-09-17 | — | — | EP | disclosed |
| US-5594021-A | VASOCONSTRICTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| WO-1996031492-A1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | ME1, ME2, ME3 | CYP2A6 1997/4885ASIC3 4485/4885LOXL2 1689/4885 |
| US-20010021714-A1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | EDNRA, EDNRB, NPSR1 | CYP2A6 3363/4885ASIC3 1684/4885LOXL2 3837/4885 |
| US-11225480-B2 | Malic enzyme inhibitors | ME1, RNASE1, ME2 | CYP2A6 2044/4885ASIC3 4318/4885LOXL2 2256/4885 |
| US-20220127266-A1 | MALIC ENZYME INHIBITORS | ME1, ME2, ME3 | CYP2A6 1997/4885ASIC3 4485/4885LOXL2 1689/4885 |
| US-20110144090-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | CYP2A6 523/4885ASIC3 4370/4885LOXL2 918/4885 |
| US-20120196845-A1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, CHRNA5 | CYP2A6 593/4885ASIC3 1308/4885LOXL2 4821/4885 |
| US-20120190868-A1 | SUBSTITUTED BENZOCHALCOGENOACENE COMPOUND, THIN FILM COMPRISING THE COMPOUND, AND ORGANIC SEMICONDUCTOR DEVICE INCLUDING THE THIN FILM | EBPL, SAAL1, APOL1 | CYP2A6 829/4885ASIC3 1888/4885LOXL2 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.